Dabrafenib

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2035 publications

A rare case of Rosai-Dorfman disease involving the pituitary stalk and presenting initially with diabetes insipidus

A rare case of Rosai-Dorfman disease involving the pituitary stalk and presenting initially with diabetes insipidus

Journal: Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
Published: September 06, 2026

Drug repurposing for TAK1 inhibition in inflammatory diseases and cancer: virtual screening identifies nilotinib and dabrafenib as potential candidates.

Drug repurposing for TAK1 inhibition in inflammatory diseases and cancer: virtual screening identifies nilotinib and dabrafenib as potential candidates.

Journal: Journal of receptor and signal transduction research
Published: September 04, 2026

Tissue-Agnostic Cancer Therapy Approvals.

Tissue-Agnostic Cancer Therapy Approvals.

Journal: Hematology/oncology clinics of North America
Published: September 02, 2026

Successful retreatment with dabrafenib and trametinib for cardiac metastases of BRAF-mutated melanoma after adjuvant therapy.

Successful retreatment with dabrafenib and trametinib for cardiac metastases of BRAF-mutated melanoma after adjuvant therapy.

Journal: European journal of dermatology : EJD
Published: August 28, 2026

Treatment of Erdheim-Chester disease from the perspective in 2026.

Treatment of Erdheim-Chester disease from the perspective in 2026.

Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: August 28, 2026

Recent Advances in the Classification and Treatment of Pediatric Gliomas

Recent Advances in the Classification and Treatment of Pediatric Gliomas

Journal: No shinkei geka. Neurological surgery
Published: August 16, 2026

Cancer Genomic Medicine in Neuro-Oncology Practice

Cancer Genomic Medicine in Neuro-Oncology Practice

Journal: No shinkei geka. Neurological surgery
Published: August 16, 2026

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

COMBI-I: Long-Term Overall Survival With Spartalizumab Plus Dabrafenib and Trametinib in BRAF V600-Mutant Advanced Melanoma.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 12, 2026

Practical management of BRAF inhibitors in glioma: toxicity and resistance.

Practical management of BRAF inhibitors in glioma: toxicity and resistance.

Journal: CNS oncology
Published: August 03, 2026

Development of a human melanoma organoid-containing skin-on-a-chip model for in vitro drug testing and personalized medicine.

Development of a human melanoma organoid-containing skin-on-a-chip model for in vitro drug testing and personalized medicine.

Journal: Biofabrication
Published: July 21, 2026

Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report.

Successful Dabrafenib Plus Trametinib Treatment in a Patient with Braf V600e Mutation-Positive Mixed Invasive Mucinous and Nonmucinous Adenocarcinoma of the Lung: A Case Report.

Journal: Internal medicine (Tokyo, Japan)
Published: July 12, 2026

Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway

Gilteritinib enhances the inhibitory effect of dabrafenib on anaplastic thyroid carcinoma cells by suppressing the AXL signaling pathway

Journal: Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
Published: July 06, 2026
Showing 1-12 of 2,035

Last Updated: 09/26/2026